期刊文献+

ERCP术后胰腺炎的防治 被引量:14

PREVENTION AND TREATMENT FOR POST ERCP PANCREATITIS
下载PDF
导出
摘要 目的 探讨内窥镜逆行胰胆管造影 (ERCP)术后胰腺炎乌司他丁 (Ulinastatin,UTI)的防治作用。方法 对1 998年 1月~ 2 0 0 3年 3月我院住院行 ERCP术 1 6 4例病人作回顾性分析总结。结果  1 6 4例行 ERCP术病人随机分为三组 :对照组 6 2例 ,乌司他丁组 6 8例 ,生长抑素组 34例。1 34例插管成功 ,成功率 82 .0 % ,其中胆管、胰管均显影 6 6例 ,胆管显影 4 6例 ,胰管显影 5 2例 ,在胆管显影的 1 1 2例中 ,70例总胆管有扩张 ,直径≥ 1 0 m m,4 2例总胆直径正常 <1 0 m m。预防用药组 ER-CP术后 2 h血清淀粉酶 (乌司他丁 2 2 6 .5± 2 6 2 .9U/ L,生长抑素 2 6 4 .0± 2 0 4 .5 U/ L)、2 4 h血清淀粉酶 (乌司他丁 2 92 .4±31 9.6 U/ L,生长抑素 2 82 .7± 2 93.8U/ L)明显低于对照组组 (5 2 2 .2± 4 96 .2 U/ L,5 0 6 .1± 5 5 9.8U/ L,P<0 .0 1 ) ;乌司他丁组、生长抑素组 ERCP术后 2 h、2 4 h血清淀粉酶水平亦明显高于术前水平 (P<0 .0 5 )。结论 乌司他丁通过减少胰液的分泌量和降低胰酶的浓度 ,能够有效防治 Objective To investigate the role of Ulinastatin in treatment and prevention to post ERCP.Methods We reviewed 164 patients examined by ERCP in our hospital from January 1998 to March 2003,retrospectively.Results 164 cases were divided into 3 teams,team placebo(62 cases)?team Ulinastation(68 cases)and team somatostatin(34 cases).134 cases were intubated successfully,bile duct were expanded in 70 cases,diameter≥10 mm,bile duct were normal in 52 cases.The level of blood serum amylase(Ulinastatin 226.5±262.9 U/L,somatostatin 264.0±204.5 U/L)after 2 hours and 24 hours (Ulinastatin 292.4±319.6 U/L,somatostatin 282.7±293.8 U/L)post ERCP with preventive drugs,were remarkable lower than the level of team placebo(522.2±496.2 U/L,506.1±559.8 U/L, P <0.01).The level of blood serum amylase after 2 hours and 24 hours post ERCP were remarkable higher than the preoperative level.Conclusion Ulinastatin could effectively prevent and cure to post ERCP pancreatits through lessening excretion dose and concentration of pancreatic juice.
出处 《肝胆外科杂志》 2004年第2期101-103,共3页 Journal of Hepatobiliary Surgery
关键词 内窥镜逆行胰胆管造影 胰腺炎 乌司他丁 Endoscopic retrograde cholangiopancreatography(ERCP) Pancreatitis Ulinastatin(UTI)
  • 相关文献

参考文献6

  • 1Niederau C,Pohlmann U,Lubke H,et al.Prophylactic antibotic treatment in therapeutic or complicated diagnostic ERCP:results of a randomized controlled clinical study [J].Gastrointest Endosc,1994,40:533-537.
  • 2Loperfido S,Angelini G,Benedteei G,et al.Major early complications from diagnostic and therapeutic ERCP:a prospective multicenter study [J].Gastrointest Endosc,1998,48:1-10.
  • 3李兆申,许国铭,钱煦岱,孙振兴.胰腺疾病患者ERCP术后并发高淀粉酶血症及急性胰腺炎临床对比研究[J].中华消化内镜杂志,1999,16(2):75-77. 被引量:89
  • 4Johnson GK,Geenen JE,Johanson JF,et al.Evaluation of post ERCP pancreatitis:potential causes woted during controlled study of differing contrast media.Midwest pancreatobiliary study group[J].Gastrointest Endosc,1997,46:217-222.
  • 5Suzuki M,Kobayashi H,Tannaka Y,et al.Structure and function analysis of urinarytrypin inhibitor(UTI):identification of binding domains and signaling property of UTI by analysis of trunctated proteins [J].Biochim Biophys Acta,2001,1547:26-36.
  • 6曾文红,白国强.乌司他丁研究进展[J].中华肝胆外科杂志,2001,7(1):52-54. 被引量:143

二级参考文献5

  • 1Kobayashi H,Shinohara H,Gotoh J,et al.Anti-metastasis therapy by urinary tyrpsin inhibitor in combination with an anti-cancer agent[].British Journal of Cancer.1995
  • 2Hiyama A,Takeda J,Kotake Y,et al.A human urinary protease inhibitor (ulinastatin) inhibits neurrophil extracellular release of elastase during cardiopulmonary bypasss[].Journal of Cardiothoracic and Vascular Anesthesia.1997
  • 3Kobayashi H,Shinohara H,Fujie M,et al.Inbibition of metastasis of lewis lung carcinoma by urinary trapsin inhibitor in experimental and spontaneous metastasis models[].International Journal of Cancer.1995
  • 4李兆申,许国铭,孙振兴,邹晓平,金震东,谢苏庆.小剂量生长抑素预防ERCP术后高淀粉酶血症及胰腺炎的临床研究[J].第二军医大学学报,1997,18(5):426-427. 被引量:33
  • 5鞠金涛,李兆申,许国铭.内镜下乳头括约肌切开术常见并发症研究近况[J].国外医学(消化系疾病分册),1998,18(2):95-98. 被引量:35

共引文献229

同被引文献130

引证文献14

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部